Cargando…
Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals
The emerging COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised a global catastrophe. To date, there is no specific antiviral drug available to combat this virus, except the vaccine. In this study, the main protease (M(pro)) required for SARS-CoV-2 vi...
Autores principales: | Sun, Le-Yun, Chen, Cheng, Su, Jianpeng, Li, Jia-Qi, Jiang, Zhihui, Gao, Han, Chigan, Jia-Zhu, Ding, Huan-Huan, Zhai, Le, Yang, Ke-Wu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026246/ https://www.ncbi.nlm.nih.gov/pubmed/33915460 http://dx.doi.org/10.1016/j.bioorg.2021.104889 |
Ejemplares similares
-
Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals
por: Xu, Yin-Sui, et al.
Publicado: (2022) -
The Mpro structure-based modifications of ebselen derivatives
for improved antiviral activity against SARS-CoV-2 virus
por: Qiao, Zhen, et al.
Publicado: (2021) -
Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2
por: Weglarz-Tomczak, Ewelina, et al.
Publicado: (2021) -
Ebselen, a new candidate therapeutic against SARS-CoV-2
por: Haritha, C.V., et al.
Publicado: (2020) -
Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease
por: Menéndez, Cintia A., et al.
Publicado: (2020)